The vaccine development sector is experiencing pullback in research and job cuts as a result of shifting government policy and investor hesitancy. Companies across the United States – from Moderna in Massachusetts to smaller manufacturers in Texas and San Diego – are scaling back operations, pausing expansions, and laying off staff. These changes have been attributed to the Trump administration’s dismantling of long-standing federal support for vaccine development, a move which industry leaders and investors say is dampening innovation.
Concerns Over Policy Shift
The appointment of Robert F. Kennedy Jr. as the next health secretary in November 2024 triggered alarm among public health experts, given his history of skepticism toward vaccines. Now, these concerns are materializing as companies adjust to a new landscape where federal backing is diminishing.
Declining Investment and Innovation
Executives and investors report a growing reluctance to invest in vaccine technologies. Moderna’s president, Dr. Stephen Hoge, stated that “there will be less invention, investment and innovation in vaccines generally, across all the companies.” The shift in federal support has led to declining sales for major manufacturers, while smaller companies face even more acute pressure, with volatile stock performances reflecting the uncertainty.
Administration Response
The Trump administration maintains that it is not actively discouraging vaccine innovation. However, the reality on the ground suggests otherwise, as investors retreat from a sector perceived as increasingly unstable. The long-term consequences of this policy change could include reduced capacity for pandemic preparedness and slower development of new vaccines for emerging diseases.
The decline in federal support for vaccine development is already impacting industry growth, investment, and employment, signaling a potential setback for public health innovation.
